American Century Companies Inc. Purchases 14,825 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

American Century Companies Inc. increased its position in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 9.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 176,367 shares of the company’s stock after buying an additional 14,825 shares during the quarter. American Century Companies Inc.’s holdings in MaxCyte were worth $734,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Catalyst Funds Management Pty Ltd bought a new position in MaxCyte in the fourth quarter valued at $74,000. Verition Fund Management LLC boosted its stake in shares of MaxCyte by 39.5% during the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock worth $83,000 after buying an additional 6,045 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of MaxCyte by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company’s stock valued at $93,000 after acquiring an additional 2,154 shares in the last quarter. SG Americas Securities LLC increased its position in shares of MaxCyte by 25.9% in the fourth quarter. SG Americas Securities LLC now owns 47,805 shares of the company’s stock valued at $199,000 after acquiring an additional 9,836 shares during the last quarter. Finally, Franklin Resources Inc. bought a new stake in MaxCyte during the third quarter worth about $260,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Trading Up 10.3 %

NASDAQ MXCT opened at $2.58 on Friday. The company has a market cap of $274.29 million, a price-to-earnings ratio of -7.59 and a beta of 1.39. The company has a 50 day moving average of $3.34 and a 200-day moving average of $3.77. MaxCyte, Inc. has a 1-year low of $2.21 and a 1-year high of $5.26.

Analyst Ratings Changes

A number of research firms have weighed in on MXCT. Stifel Nicolaus decreased their price target on MaxCyte from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, March 12th. BTIG Research set a $6.00 target price on shares of MaxCyte and gave the company a “buy” rating in a research note on Wednesday, March 12th.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.